ClinicalTrials.gg

Program

CRD-4730

A development code.

Its studies are mostly in Heart Failure · Tachycardia, Ventricular · Heart Defects, Congenital, led by Cardurion Pharmaceuticals.

Furthest: phase 2, since Aug 8, 20233 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cardurion Pharmaceuticals32 open or runningphase 2since Aug 8, 2023Aug 8, 2023Apr 2027phase 2 · NCT06658899

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2023First study: phase 2 study in Heart Defects, CongenitalFirst studyNCT06005428 · 7 enrolled · United States, Canada, France and more
  2. Oct 23, 2024Phase 2 study in Polymorphic Catecholaminergic Ventricular TachycardiaNCT06658899 · 12 planned · United States, Canada, France and more
  3. Jul 17, 2026Phase 2 study in Heart FailureNCT07750873 · 525 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Polymorphic Catecholaminergic Ventricular TachycardiaNCT06658899
  2. Sep 2028Primary completion: phase 2 study in Heart FailureNCT07750873

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07750873Heart Failure · United States2RecruitingSep 2028525
NCT06658899Polymorphic Catecholaminergic Ventricular Tachycardia · United States, Canada, France and more2RecruitingApr 202712
NCT06005428Heart Defects, Congenital · United States, Canada, France and more2TerminatedMay 31, 20257

How it is read

Names in the registry

  • “CRD-4730”, 3 entries

Codes read as this program: CRD4730.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.